Jefferies analyst Akash Tewari raised the price target on Terns Pharmaceuticals (NASDAQ: TERN) to $30.00 (from $22.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Momentum Movers

Terns Pharmaceuticals Inc. (TERN) Climbs 29% Following Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of ObesitySeptember 9, 2024 8:07 AM Form 8-K Terns Pharmaceuticals, For: Sep 09September 9, 2024 7:17 AM Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of ObesitySeptember 9, 2024 7:05 AM Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of ObesitySeptember 9, 2024 7:05 AM TD Cowen Reiterates Buy Rating on Terns Pharmaceuticals (TERN)September 6, 2024 9:18 AM Micron, Oracle are new Top Picks at MizuhoSeptember 6, 2024 8:34 AM Mizuho Adds New Names to Top Pick ListSeptember 6, 2024 6:26 AM